Welcome to our dedicated page for Syndax Pharmaceuticals news (Ticker: SNDX), a resource for investors and traders seeking the latest updates and insights on Syndax Pharmaceuticals stock.
Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) is a commercial-stage biopharmaceutical company whose news flow centers on cancer drug development, regulatory milestones, and commercialization updates. The company’s announcements emphasize progress with its two FDA-approved therapies: Revuforj® (revumenib), an oral menin inhibitor for specific relapsed or refractory acute leukemias, and Niktimvo™ (axatilimab-csfr), a CSF-1 receptor-blocking antibody for chronic graft-versus-host disease after at least two prior systemic therapies.
News for SNDX often covers quarterly and annual financial results, product revenue trends for Revuforj and Niktimvo, and guidance on research and development as well as selling, general and administrative expenses. Investors can follow updates on clinical trial milestones, such as Phase 2 and Phase 3 studies of revumenib in newly diagnosed and relapsed or refractory NPM1-mutated and KMT2A-rearranged AML, and trials of axatilimab in chronic GVHD and idiopathic pulmonary fibrosis.
Press releases also highlight regulatory events, including FDA approvals and label expansions, inclusion of revumenib in clinical practice guidelines, and special designations such as Orphan Drug, Fast Track, and Breakthrough Therapy. Scientific and medical conference activity is another recurring theme, with multiple abstracts and oral presentations at meetings like the American Society of Hematology and appearances at investor conferences and healthcare forums.
In addition, Syndax issues news on collaborations and access initiatives, such as its agreement with the World Orphan Drug Alliance to launch a multi-regional Managed Access Program for Revuforj outside the United States. For investors and observers tracking SNDX, the news stream provides insight into commercial performance, pipeline evolution, partnership activity, and the company’s stated path toward profitability.
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company, announced on June 3, 2024, that it granted inducement awards to purchase up to 499,200 shares of common stock to fifty-three new employees. These awards were given under the Company's 2023 Inducement Plan on June 1, 2024. The stock options will vest over four years, with 25% vesting on the one-year anniversary of the vesting commencement date and the remaining shares vesting monthly thereafter over 36 months. The vesting is contingent upon the employee's continued service with Syndax.
Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company focused on cancer therapies, has appointed Aleksandra Rizo, M.D., Ph.D., to its Board of Directors effective May 15, 2024. Dr. Rizo, who has extensive experience in clinical development and commercialization of hematology drugs, will replace Dr. Briggs Morrison. Dr. Rizo currently serves as President and CEO of Vividion and has previously held leadership roles at Geron and Celgene Syndax is transitioning to a commercial-stage organization with the potential launch of two new treatments, Revumenib and Axatilimab, in 2024. Dr. Rizo will contribute her expertise as Syndax aims for long-term success in clinical and corporate development.
Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on May 16, 2024. The event will be live webcasted on the company's website, with a replay available for a time.
Syndax Pharmaceuticals reported its first-quarter financial results for 2024, highlighting the NDA filing for revumenib and BLA filing for axatilimab with Priority Reviews. The Company anticipates significant milestones with pivotal data from the AUGMENT-101 trial and potential approvals in the third quarter. The CEO emphasized the value-creating potential of launching innovative therapies into multi-billion-dollar markets. Syndax continues to focus on building a strong team for successful commercialization.
Syndax Pharmaceuticals granted inducement awards to six new employees to purchase up to 100,600 shares of common stock under the 2023 Inducement Plan. The stock options will vest over four years, with gradual vesting conditions tied to the employees' continued service relationship.
Syndax Pharmaceuticals (Nasdaq: SNDX) will announce its first quarter 2024 financial results and provide a business update on May 8, 2024. The company will host a conference call and webcast to discuss the financial results and business progress.
Summary not available.
Summary not available.
Summary not available.
Summary not available.